Bristol Myers Squibb (CELG-RI) Non-Current Deferred Tax Liability (2009 - 2026)

Bristol Myers Squibb (CELG-RI) has reported Non-Current Deferred Tax Liability for 15 consecutive years, with $222.0 million the latest figure, recorded in Q2 2026.

• In Q2 2026, Non-Current Deferred Tax Liability fell 10.12% year-over-year to $222.0 million; the TTM figure through Jun 2026 stood at $222.0 million (down 10.12% YoY), while the FY2025 annual figure was $222.0 million, down 95.14% from the prior year.
• Non-Current Deferred Tax Liability improved to $222.0 million in Q2 2026 per CELG-RI's latest filing, from $211.0 million in the prior quarter.
• Across five years, Non-Current Deferred Tax Liability topped out at $5.0 billion in Q4 2022 and bottomed at $211.0 million in Q1 2026.
• Historically, Non-Current Deferred Tax Liability has averaged $1.6 billion across 5 years, with a median of $451.5 million in 2024.
• Annual changes were most pronounced in 2024 — Non-Current Deferred Tax Liability climbed 7.77% — and 2025, when it sank 95.14%.
• Bristol Myers Squibb's Non-Current Deferred Tax Liability stood at $5.0 billion in 2022, then declined by 1.27% to $4.9 billion in 2023, then slipped by 6.77% to $4.6 billion in 2024, then tumbled by 95.14% to $222.0 million in 2025, then changed by 0.0% to $222.0 million in 2026.
• Business Quant data shows CELG-RI's Non-Current Deferred Tax Liability at $222.0 million in Q2 2026, $211.0 million in Q1 2026, and $222.0 million in Q4 2025.